J Korean Ophthalmol Soc.  2016 Mar;57(3):438-444. 10.3341/jkos.2016.57.3.438.

Comparison of Bevacizumab and Combined Low-dose Bevacizumab and Triamcinolone in Central Retinal Vein Occlusion

• Kim BJ
• Kim HW
• Han YS
• Park JM
• Chung IY

• KMID: 2213245
• DOI: http://doi.org/10.3341/jkos.2016.57.3.438

Abstract

PURPOSE
To report the effects and intraocular pressure (IOP) results of intravitreal injection of bevacizumab alone compared with intravitreal low-dose bevacizumab combined with low-dose triamcinolone injection in patients with central retinal vein occlusion.
METHODS
In total, 40 eyes of 40 patients diagnosed with central retinal vein occlusion were evaluated. Of these, 20 eyes of 20 patients were injected with intravitreal bevacizumab (1.25 mg/0.05 mL), and 20 eyes of 20 patients were injected with low-dose bevacizumab (0.625 mg/0.025 mL) combined with low-dose triamcinolone (1 mg/0.025 mL). The best corrected visual acuity (BCVA), central macular thickness (CMT), and IOP of treated eyes were measured before injection and at 1 month, 2 months, and 3 months after injection.
RESULTS
In both the intravitreal bevacizumab and the low-dose bevacizumab combined with low-dose triamcinolone groups, CMT decreased significantly at 1 month, 2 months, and 3 months after injection (p < 0.05). In addition, in both groups, neither IOP nor BCVA decreased significantly at 1 month, 2 months, or 3 months after injection (p > 0.05). The BCVA, IOP, and CMT at 1 month, 2 months, and 3 months after injection showed no significant differences between the intravitreal bevacizumab group and the low-dose bevacizumab combined with low-dose triamcinolone group (p > 0.05).
CONCLUSIONS
The CMT of both groups decreased significantly, and BCVA of both groups increased significantly in patients with central retinal vein occlusion. Injection of low-dose intravitreal bevacizumab combined with low-dose intravitreal triamcinolone may be useful for the treatment of central retinal vein occlusion.

Keyword

Central retinal vein occlusion; Intravitreal bevacizumab injection; Intravitreal triamcinolone injection

MeSH Terms

Humans
Intraocular Pressure
Intravitreal Injections
Retinal Vein*
Triamcinolone*
Visual Acuity
Bevacizumab
Triamcinolone

Reference

References

1. Glacet-Bernard A, Coscas G, Chabanel A, et al. Prognostic factors for retinal vein occlusion: prospective study of 175 cases. Ophthalmology. 1996; 103:551–60.

2. Lattanzio R, Torres Gimeno A, Battaglia , Parodi M, Bandello F. Retinal vein occlusion: current treatment. Ophthalmologica. 2011; 225:135–43.

3. Mitchell P, Smith W, Chang A. Prevalence and associations of retinal vein occlusion in Australia. The Blue Mountains Eye Study. Arch Ophthalmol. 1996; 114:1243–7.

4. Klein R, Klein BE, Moss SE, Meuer SM. The epidemiology of retinal vein occlusion: the Beaver Dam Eye Study. Trans Am Ophthalmol Soc. 2000; 98:133–41. discussion 141-3.

5. Rogers S, McIntosh RL, Cheung N, et al. The prevalence of retinal vein occlusion: pooled data from population studies from the United States, Europe, Asia, and Australia. Ophthalmology. 2010; 117:313–9.e1.

6. Laouri M, Chen E, Looman M, Gallagher M. The burden of disease of retinal vein occlusion: review of the literature. Eye (Lond). 2011; 25:981–8.

7. Park H, Ohn YH, Shin H. Clinical characteristics and classifications of retinal vein occlusion. J Korean Ophthalmol Soc. 1996; 37:1022–31.

8. Merin S, Ber I, Ivry M. Retinal ischemia (capillary nonperfusion) in diabetic retinopathy of patients with and without systemic hypertension. Ophthalmologica. 1978; 177:76–81.

9. Domalpally A, Blodi BA, Scott IU, et al. The Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) study system for evaluation of optical coherence tomograms: SCORE study report 4. Arch Ophthalmol. 2009; 127:1461–7.

10. Scott IU, Ip MS, VanVeldhuisen PC, et al. A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with standard care to treat vision loss associated with macular Edema secondary to branch retinal vein occlusion: the Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) study report 6. Arch Ophthalmol. 2009; 127:1115–28.

11. Kim H, Moon S, Kang J, Yoon H. Intravitreal triamcinolone versus bevacizumab for treatment of macular edema secondary to branch retinal vein occlusion. J Korean Ophthalmol Soc. 2010; 51:1071–6.

12. Antcliff RJ, Spalton DJ, Stanford MR, et al. Intravitreal triamcinolone for uveitic cystoid macular edema: an optical coherence tomography study. Ophthalmology. 2001; 108:765–72.

13. Young S, Larkin G, Branley M, et al. Safety and efficacy of intra-vitreal triamcinolone for cystoid macular oedema in uveitis. Clin Experiment Ophthalmol. 2001; 29:2–6.

14. Jonas JB, Söfker A. Intraocular injection of crystalline cortisone as adjunctive treatment of diabetic macular edema. Am J Ophthalmol. 2001; 132:425–7.

15. Jonas JB, Hayler JK, Panda-Jonas S. Intravitreal injection of crystalline cortisone as adjunctive treatment of proliferative vitreoretinopathy. Br J Ophthalmol. 2000; 84:1064–7.

16. Danis RP, Ciulla TA, Pratt LM, Anliker W. Intravitreal triamcinolone acetonide in exudative age-related macular degeneration. Retina. 2000; 20:244–50.

17. Challa JK, Gillies MC, Penfold PL, et al. Exudative macular degeneration and intravitreal triamcinolone: 18 month follow up. Aust N Z J Ophthalmol. 1998; 26:277–81.

18. Tao Y, Hou J, Jiang YR, et al. Intravitreal bevacizumab vs triamcinolone acetonide for macular oedema due to central retinal vein occlusion. Eye (Lond). 2010; 24:810–5.

19. Fish GE. Intravitreous bevacizumab in the treatment of macular edema from branch retinal vein occlusion and hemisphere retinal vein occlusion (an AOS thesis). Trans Am Ophthalmol Soc. 2008; 106:276–300.

20. Ehrlich R, Ciulla TA, Moss AM, Harris A. Combined treatment of intravitreal bevacizumab and intravitreal triamcinolone in patients with retinal vein occlusion: 6 months of follow-up. Graefes Arch Clin Exp Ophthalmol. 2010; 248:375–80.

21. Choi SW, Kim HW, Yun IH. Intravitreal bevacizumab treatment of macular edema in central retinal vein occlusion. J Korean Ophthalmol Soc. 2010; 51:707–15.

22. Prager F, Michels S, Kriechbaum K, et al. Intravitreal bevacizumab (Avastin) for macular oedema secondary to retinal vein occlusion: 12-month results of a prospective clinical trial. Br J Ophthalmol. 2009; 93:452–6.

23. Beutel J, Ziemssen F, Lüke M, et al. Intravitreal bevacizumab treatment of macular edema in central retinal vein occlusion: one-year results. Int Ophthalmol. 2010; 30:15–22.

24. Fischer S, Renz D, Schaper W, Karliczek GF. In vitro effects of dexamethasone on hypoxia-induced hyperpermeability and expression of vascular endothelial growth factor. Eur J Pharmacol. 2001; 411:231–43.

25. Gregori NZ, Rosenfeld PJ, Puliafito CA, et al. One-year safety and efficacy of intravitreal triamcinolone acetonide for the management of macular edema secondary to central retinal vein occlusion. Retina. 2006; 26:889–95.

26. Ip MS, Kumar KS. Intravitreous triamcinolone acetonide as treat ment for macular edema from central retinal vein occlusion. Arch Ophthalmol. 2002; 120:1217–9.

27. Chang MW, Kim SW, Oh IK, et al. Intravitreal tamcinolone injection with or without bevacizumab for diabetic macular edema. J Korean Ophthalmol Soc. 2008; 49:1269–74.

28. Kim BS, Chung IY, Park JM, et al. Comparison of intravitreal bevacizumab alone injection and intravitreal combination low-dose bevacizumab-triamcinolone injection or diabetic macular edema. J Korean Ophthalmol Soc. 2014; 55:1155–61.

29. Lee K, Jung H, Sohn J. Comparison of injection of intravitreal drugs with standard care in macular edema secondary to branch retinal vein occlusion. Korean J Ophthalmol. 2014; 28:19–25.